Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Unicycive Therapeutics, Inc.: Filing of Certificate of Designation for Series B-1 Preferred Stock and Series B-2 Preferred Stock, setting forth rights, preferences, and limitations (effective 2024-03-14).
- Change
- charter amendment
- Effective
- 2024-03-14
Exact text from the filing
Pursuant to the terms of the Purchase Agreement, on March 14, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 50,000 shares of its authorized and unissued preferred stock as Series B-1 Preferred Stock
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Unicycive Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Aggregate purchase price of $50 million for 50,000 shares of Series B Convertible Preferred Stock at (effective 2024-03-13).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- Aggregate purchase price of $50 million for 50,000 shares of Series B Convertible Preferred Stock at
- Effective
- 2024-03-13
Exact text from the filing
On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), 50,000 shares of its Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share with an initial conversion price of $1.00 per share, subject to adjustment (the “ Conversion Price”) , for an aggregate purchase price of $50 million.
View on SEC.gov